Abstract
Abstract
68Ga-labeled DOTA-ibandronic acid (68Ga-DOTA-IBA) is a novel PET agent developed for bone tumors. In addition, 68Ga-DOTA-IBA uptake in nonosseous findings has also been reported. Herein, we present a case of 68Ga-DOTA-IBA uptake in primary prostate adenocarcinoma.
Publisher
Ovid Technologies (Wolters Kluwer Health)